Clinical Trial Update: A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial results update for Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory primary mediastinal large B-cell lymphoma, with the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Adcetris (brentuximab vedotin) (brentuximab vedotin)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Primary Mediastinal Large B Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-06-26